Pandion Therapeutics Inc. Common Stock
PAND
PAND was delisted on the 31st of March, 2021.
75 hedge funds and large institutions have $515M invested in Pandion Therapeutics Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 14 closing their positions.
227% more capital invested
Capital invested by funds: $158M → $515M (+$357M)
193% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 14
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
56% more funds holding
Funds holding: 48 → 75 (+27)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$27.9M |
| 2 |
VI
Versor Investments
New York
|
+$26.9M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$26.2M |
| 4 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$18.9M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$34.5M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$31.3M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$26.3M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$20.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$14.9M |
PAND Hedge Fund Activity: Q1 2021 in Review
75 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Pandion Therapeutics Inc. Common Stock (PAND) for Q1 2021, worth a combined $515M — up 227% from $158M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new PAND positions and 14 closed out — a net gain of 27 holders — while 21 added to existing stakes and 9 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $27.9M. The largest seller was OrbiMed, cutting an estimated $34.5M.
- 75 institutional investors held Pandion Therapeutics Inc. Common Stock (PAND) as of Q1 2021, up from 48 in Q4 2020.
- Funds reported $515M of Pandion Therapeutics Inc. Common Stock stock for Q1 2021, up 227% quarter-over-quarter.
- 41 funds opened new Pandion Therapeutics Inc. Common Stock positions in Q1 2021 and 14 closed out, a net change of +27 holders.
- The largest Pandion Therapeutics Inc. Common Stock buyer in Q1 2021 was Goldman Sachs, an estimated $27.9M added.
- The largest Pandion Therapeutics Inc. Common Stock seller in Q1 2021 was OrbiMed, an estimated $34.5M sold.
Based on aggregated 13F filings for Q1 2021.